[1] Luiza, V.L.; Chaves, L.A.; Silva, R.M.; Emmerick, I.C.; Chaves, G.C.; Fonseca de Araújo, S.C.; Moraes, E.L.; Oxman, A.D. Pharmaceutical policies: effects of cap and co-payment on rational use of medicines. Cochrane Database Syst. Rev. 2015, 8, CD007017.
[2] Brekke, K.R.; Grasdal, A.L.; Holmås, T.H. Regulation and pricing of pharmaceuticals: Reference pricing or price cap regulation? Eur. Econ. Rev. 2009, 53, 170-185.
[3] Zweifel, P.; Crivelli, L. Price regulation of drugs: Lessons from Germany. J. Regul. Econ. 1996, 10, 257-273.
[4] Stargardt, T. The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany. Eur. J. Health Econ. 2010, 11, 267-277.
[5] Grootendorst, P.V.; Dolovich, L.; Holbrook, M.A.; Levy, A.; O’Brien, B.J. The Impact of Reference Pricing of Cardiovascular Drugs on Health Care Costs and Health Outcomes: Evidence from British Columbia -- Volume II: Technical Report. 2002.
[6] Schneeweiss, S.; Walker, A.M.; Glynn, R.J.; Maclure, M.; Dormuth, C.; Soumerai, S.B. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. N. Engl. J. Med. 2002, 346, 822-829.
[7] Yu, J.X.; Que, M.Y.; Wang, S.; Yin, T.; Wang, J.; Yang, S.; Jiang, B. Framework and local experience of pharmaceutical reimbursement criteria policy (PRCP) in China. Chin. Pharm. Sci. 2017, 26, 390-394.
[8] Fujian Provicial Medical Security Management Committee Office. Chinaemed. 2017. This article can be found online at http://www.chinaemed.com/Province/fujian/Docs/Dynamic/Province/20860.
[9] Acosta, A.; Ciapponi, A.; Aaserud, M.; Vietto, V.; Austvoll-Dahlgren, A.; Kösters, J.P.; Vacca, C.; Machado, M.; Diaz Ayala, D.H.; Oxman, A.D. Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies. Cochrane Database Syst. Rev. 2014, 16, CD005979.
[10] Yin, T.; Jiang, B. Effects of drug procurement under cap price policy in Sanming. Chin. Pharm. Sci. 2018, 27, 799-804.
[11] Zhou, Z.Y.; Jiang, Y.L.; Gan, X.D.; Jiao, S.G. Application of DDDs in Evaluating the Rational use of Antimicrobial drugs. Proc. Clin. Med. 2014, 23, 521-523.
[12] Yi, H.; Xiao, Z.H.; Yuan, H.Y. Application of antimicrobials with DDDs in our hospital in 2007. Mod. Prev. Med. 2009, 36, 1190-1191.
[13] Hyman, R. Quasi-experimentation: design and analysis issues for field settings (book). J. Pers. Assess. 1982, 46, 96-97. |